Sanofi, Re­gen­eron boast PhI­II win with Dupix­ent in COPD, clear­ing first bar for ex­pan­sion

Dupix­ent, the block­buster an­ti-in­flam­ma­to­ry drug from Sanofi and Re­gen­eron, has cleared a high-stakes Phase III study in chron­ic ob­struc­tive pul­monary dis­ease, the com­pa­nies an­nounced Thurs­day morn­ing.

If they hold up in a sec­ond, iden­ti­cal tri­al, the da­ta pave the way for Dupix­ent to be­come the first bi­o­log­ic to treat pa­tients whose COPD re­mains un­con­trolled de­spite be­ing on max­i­mal stan­dard-of-care in­haled ther­a­py — the pa­tient pop­u­la­tion stud­ied in the piv­otal pro­gram. The com­pa­nies had spot­light­ed this as a key read­out as they look to ex­pand the Dupix­ent fran­chise and ex­plore its full po­ten­tial.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER